Literature DB >> 10571336

The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists.

J D Trobe1, P C Sieving, K E Guire, A M Fendrick.   

Abstract

OBJECTIVE: To determine whether the Optic Neuritis Treatment Trial (ONTT) results have altered the practice patterns of ophthalmologists and neurologists.
DESIGN: Mail survey. PARTICIPANTS: A random sample of 987 ophthalmologists and 900 neurologists practicing in the United States were mailed a questionnaire that inquired into decision-making with regard to management of optic neuritis before and after the publication of the ONTT results. MAIN OUTCOME MEASURES: Responses received from 202 ophthalmologists and 244 neurologists, a response rate of 47%.
RESULTS: Following the ONTT reports, nearly all ophthalmologists and neurologists have reduced their use of oral prednisone alone, substituting a regimen that includes intravenous methylprednisolone. A large proportion of practitioners in both specialties mistakenly believe that intravenous methylprednisolone treatment improves final visual outcome. Only 7% of neurologists and 36% of ophthalmologists (P = 0.0001) are adhering to the ONTT suggestion to use magnetic resonance imaging as a basis for initiating treatment.
CONCLUSIONS: The ONTT has led to a dramatic reduction in the use of oral prednisone without a preceding course of intravenous methylprednisolone in the treatment of acute optic neuritis. Ophthalmologists and neurologists have changed some of their practices without fully understanding the results of the ONTT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571336     DOI: 10.1016/S0161-6420(99)90482-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  Management of optic neuritis in Canada: survey of ophthalmologists and neurologists.

Authors:  Edward J Atkins; Carolyn D Drews-Botsch; Nancy J Newman; Olivier Calvetti; Seegar Swanson; Valérie Biousse
Journal:  Can J Neurol Sci       Date:  2008-05       Impact factor: 2.104

Review 2.  The Diagnosis and Treatment of Optic Neuritis.

Authors:  Helmut Wilhelm; Martin Schabet
Journal:  Dtsch Arztebl Int       Date:  2015-09-11       Impact factor: 5.594

3.  Adherence to Clinical Trial Supported Evaluation of Optic Neuritis.

Authors:  Elana Meer; Kenneth S Shindler; Yinxi Yu; Brian L VanderBeek
Journal:  Ophthalmic Epidemiol       Date:  2019-05-29       Impact factor: 1.648

4.  Pediatric Optic Neuritis Prospective Outcomes Study.

Authors:  Stacy L Pineles; Grant T Liu; Amy T Waldman; Elizabeth Lazar; Mark J Kupersmith; Michael X Repka
Journal:  J Neuroophthalmol       Date:  2016-06       Impact factor: 3.042

5.  Optic Neuritis.

Authors:  Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

6.  Patients' knowledge and perception on optic neuritis management before and after an information session.

Authors:  Albert I Matti; Miriam C Keane; Helen McCarl; Pamela Klaer; Celia S Chen
Journal:  BMC Ophthalmol       Date:  2010-03-21       Impact factor: 2.209

7.  Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand.

Authors:  Christian J Lueck; Helen V Danesh-Meyer; Faith J Margrie; Carolyn Drews-Botsch; Olivier Calvetti; Nancy J Newman; Valérie Biousse
Journal:  J Clin Neurosci       Date:  2008-10-30       Impact factor: 1.961

8.  Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series.

Authors:  G T Plant; N A Sibtain; D Thomas
Journal:  Mult Scler Int       Date:  2011-06-30

9.  Potential bias in ophthalmic pharmaceutical clinical trials.

Authors:  Paul Varner
Journal:  Clin Ophthalmol       Date:  2008-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.